君实生物（01877）今日盘中股价大幅拉升，涨幅一度达到5.04%，引起了市场的广泛关注。
消息面上，公司近期召开了业绩说明会，向市场详细披露了其丰富的创新药研发管线进展。其中，下一代PD-1/VEGF双抗JS207已布局多个联合治疗的临床研究，数据将陆续披露；首款国产皮下注射PD-1单抗JS001sc已进入上市申报阶段，便利性优势显著；此外，EGFR/HER3 ADC、Claudin18.2 ADC等多个重点在研药物也取得了积极进展，部分关键临床研究计划于2026年启动。这些进展凸显了公司在肿瘤治疗领域的深厚布局和长期增长潜力。
与此同时，公司控股股东、实际控制人之一兼董事长持续增持公司股份，截至最新公告日已累计增持金额超1200万元，且增持计划尚未完成，这进一步向市场传递了内部人士对公司未来发展前景的坚定信心。结合公司2025年营收显著增长、核心产品特瑞普利单抗海外市场销售表现亮眼等积极基本面，共同推动了股价在交易时段内的强势表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.